Skip to main content
. Author manuscript; available in PMC: 2015 Feb 15.
Published in final edited form as: Clin Cancer Res. 2013 Dec 13;20(4):962–971. doi: 10.1158/1078-0432.CCR-13-2218

Figure 1. CSPG4 expression in primary solid tumors and tumor-derived cell lines.

Figure 1

Panel A. Representative immunohistochemistry (IHC) and scoring of analyzed solid tumor tissue arrays. Representative melanoma and breast carcinoma samples are shown at 200X magnification. Panel B. Scoring summary of a panel of solid tumors which includes melanoma, breast carcinoma (Breast CA), HNSCC, neuroblastoma (NeuroB) and mesothelioma (MesoT). Panel C. CSPG4 mRNA expression by TCGA in a variety of solid tumors. Box plots show median, 25%/75% range, 5%/95% range, and minimum/maximum. Panel D. CSPG4 mRNA expression analysis, comparing tumor versus corresponding normal tissues, for astrocytoma/glioblastoma (GBM), HNSCC, clear cell renal carcinoma, and melanoma. Indicated P-values were calculated by t-test. Panel E. CSPG4 expression in the indicated array of melanoma cell lines as assessed by flow cytometry (FACS). Panel F. FACS analysis of CSPG4 expression in the selected mesothelioma (MILL and PHI), HNSCC (PCI-30), and breast cancer- derived (MDA-MB-231 and UACC-812) cells lines. Dotted and bold lines indicate isotype and CSPG4 mAbs, respectively.